Hardwick,, United Kingdom Clinical Trials

A listing of Hardwick,, United Kingdom clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 218 clinical trials
Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

Addenbrooke's Hospital
 (6.1 away) Contact site
  • 17 Jul, 2021
  • +180 other locations
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All …

steroid therapy
Research Site
 (6.1 away) Contact site
  • 15 Sep, 2021
  • +80 other locations
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment …

Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
 (6.1 away) Contact site
  • 24 Jul, 2021
  • +23 other locations
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

The purpose of this study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment …

Cambridge University Hospitals NHS Foundation Trust; Merz Investigational Site 0440023
 (6.1 away) Contact site
  • 15 Sep, 2021
  • +62 other locations
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

tumor necrosis factor
immunosuppressive agents
monoclonal antibodies
Cambridge University NHS Trust
 (6.1 away) Contact site
  • 02 Aug, 2021
  • +32 other locations
My Personalized Breast Screening

MyPeBS is an international randomized, open-label, multicentric, study assessing the effectiveness of a risk-based breast cancer screening strategy (using clinical risk scores and polymorphisms) compared to standard screening (according to the current national guidelines in each participating country) in detecting stage 2 or higher breast cancers. Women will be differentially …

Cambridge University Hospitals NHS Foundation Trust
 (4.1 away) Contact site
  • 03 Sep, 2021
  • +6 other locations
A Study of Biomarker-Directed Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with …

Cambridge University Hospitals NHS Trust ( Site 1306)
 (6.1 away) Contact site
  • 04 Sep, 2021
  • +93 other locations
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)

TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most …

Cambridge University Hospitals NHS Foundation Trust
 (6.1 away) Contact site
  • 24 Jan, 2021
  • 1 location
Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock

Cardiogenic shock (CGS) affects up to 10% of patients suffering acute coronary syndrome. It has a 30 day mortality of 45-50%. No pharmacological nor intervention/device trials have had any impact on this mortality in the last 20 years. The EURO SHOCK Trial (supported by the European Union Horizons 2020 programme) …

Papworth Hospital
 (5.9 away) Contact site
  • 12 May, 2021
  • +46 other locations
A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee

This is a Phase 2b randomised, double-blind, placebo-controlled, dose-response study in subjects with painful osteoarthritis (OA) of the knee. The study will assess the safety and efficacy of multiple doses of MEDI7352 compared to placebo, as well as the pharmacokinetics, pharmacodynamics and immunogenicity of MEDI7352 in subjects with moderate to …

Research Site
 (6.1 away) Contact site
  • 15 Sep, 2021
  • +59 other locations